Anthropic Ratchets Pentagon Battle: Private Deals at Risk
Anthropic has filed a federal lawsuit after being labeled a supply-chain risk by the government, arguing the move thr...
Articles — Page 1994
Ticketmaster Settlement Good News for Markets, Bad for Fans
A fresh settlement involving Ticketmaster sparked a rally in Live Nation shares, signaling investor relief but stirri...
Mark Zuckerberg Booed Ultimate: Finances After Spotlight
A single moment on camera can reveal how perception, risk, and money collide. This piece examines what the mark zucke...
TransUnion Cuts VantageScore Price to 99 Cents for Lenders
TransUnion lowers VantageScore 4.0 pricing to 99 cents per score for mortgage lenders, with free access tied to FICO ...
Logan Finance Rolls Product to Expand High-Balance Non-QM
Logan Finance rolls out a premium Open Road Elevated tier to serve high-net-worth borrowers with larger loan needs ou...
Real Brokerage Adds Diego Leader to Chief Growth Officer
The Real Brokerage is expanding its leadership with the appointment of Jason Cassity as Chief Growth Officer, a move ...
Goldman Sees $5,400 Gold: What It Means for DUST Investors
A Goldman Sachs note presents a bullish scenario where gold could hit $5,400 per ounce. The outlook reverberates thro...
Retirees Still Collecting Quarterly Dividends From Aging ETF
Dividend-focused ETFs remain a fixture for retirement income, but a shifting rate landscape tests how long these fund...
Retirees Eyeing EMLC’s 5.75% Yield, Wall Street Bets
A growing slice of retirees is looking at the EM Local Currency Bond ETF for a higher income stream. But currency swi...
Poland’s Wild Stock Market: The ETF Play to Watch Now
Poland’s wild stock market is capturing renewed interest as diversification in Europe. The iShares Poland ETF offers ...
Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...